Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.
The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use. Neurocrine also commercializes Orilissa® (elagolix), a once-daily oral therapy for endometriosis, and Oriahnn® (elagolix with estradiol and norethindrone acetate) for the management of heavy menstrual bleeding associated with uterine fibroids. In addition, Neurocrine has licensed opicapone, a catechol-O-methyltransferase inhibitor for Parkinson’s disease “OFF” episodes, in partnership with BIAL.
Beyond its approved products, Neurocrine maintains a diversified pipeline targeting conditions such as essential tremor, amyotrophic lateral sclerosis and Cushing’s syndrome. The company conducts clinical trials in North America, Europe and Asia, and leverages strategic partnerships to expand its global reach. This collaborative approach has enabled external commercialization agreements and regulatory submissions in multiple jurisdictions.
Leadership at Neurocrine is headed by President and Chief Executive Officer Kevin C. Gorman, under whose tenure the company has secured key regulatory approvals and forged licensing deals with major pharmaceutical firms. Over the years, Neurocrine has grown from a research‐focused startup into a commercial biotech organization with a mission to develop innovative therapies for challenging neurological and endocrine diseases.
AI Generated. May Contain Errors.